Story · Medicine & Biotech

STAT+: FDA approves novel Bayer drug to reduce recurrence of stroke

8 outlets · first reported by FDA Drug Safety / Drugs feed on · latest · 96 hours of coverage · 5 countries

The Food and Drug Administration on Monday approved Bayer’s drug to reduce recurrence of stroke, making available the first in a novel class of medications that hold the promise of preventing blood clots more safely. Many blood thinners aren’t used in this setting due to their increased risk of… (STAT News)

Coverage, in order

  1. first FDA Drug Safety / Drugs feed indie
    FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk

    FDA today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack.

  2. STAT News indie
    STAT+: FDA approves novel Bayer drug to reduce recurrence of stroke

    The Food and Drug Administration on Monday approved Bayer’s drug to reduce recurrence of stroke, making available the first in a novel class of medications that hold the promise of preventing blood clots more safely. Many blood thinners aren’t used in this setting due to their increased risk of…

  3. Life Science Sweden Sweden indie
    FDA approves Bayer’s first-in-class stroke drug
  4. Pharmaphorum UK indie
    Bayer bags FDA green light for stroke drug Sunharbo

    Bayer bags FDA green light for stroke drug Sunharbo Phil.Taylor Tue, 10/11/2026 - 09:36

  5. Clinica.bg BG indie bg
    FDA approves a new drug against recurrent strokeFDA одобри нов медикамент срещу повторен инсулт

    Tablets cut recurrent ischaemic stroke risk by 26%.Таблетките намаляват с 26% риска от повторен исхемичен инцидент, съобщиха от Агенцията

  6. Medical Dialogues India obscure
    FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk

    The U.S. Food and Drug Administration has approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke (a stroke…

  7. MedCity News indie study
    FDA Approves First-in-Class Bayer Drug for Reducing the Risk of Stroke

    Bayer’s asundexian, brand name Sunharbo, is the first FDA-approved drug in a new class cardiovascular medicines Approval of the once-daily pill covers secondary stroke prevention in adults.

  8. Cardiovascular Business indie
    FDA approves first-in-class drug for secondary stroke prevention

    An FDA statement called the new approval of Bayer's asundexian a "meaningful advance for patients and healthcare providers seeking a new option for secondary stroke prevention."

  9. FDA Drug Safety / Drugs feed indie
    FDA Approves First Drug to Treat Adults with Primary Membranous Nephropathy

    FDA approved Gazyva (obinutuzumab) injection to induce remission of proteinuria (protein in the urine) in adults with primary membranous nephropathy at risk of disease progression.

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.